CRISPR/Cas: exploring its impact on gene editing
Posted: 8 March 2024 | Drug Target Review, Molecular Devices | No comments yet
Tune in to this episode where we discuss the opportunities CRISPR/Cas technology offers to revolutionise drug discovery.
In this episode titled: CRISPR/Cas: exploring its impact on gene editing, we explore the latest technological advancements in the field and more.
This conversation features Dr Pietro De Angeli, Scientist at Tubingen University Hospital, and Dr Maarten Geurts, Postdoctoral Fellow at the Princess Maxima Center for Pediatric Oncology.
Key learning points:
- What comparative safety profiles exist between utilising plasmid DNA, mRNA, and ribonucleoproteins (RNPs) as delivery systems for CRISPR/Cas components in gene editing therapies?
- In what ways might the use of different ex-vivo applications affect the scalability and feasibility of large-scale gene editing treatments?
- How might the convergence of CRISPR/Cas technology with Artificial Intelligence/Machine Learning improve precision medicine?
This podcast is sponsored by Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About our speakers
Dr Pietro De Angeli
Scientist at Tubingen University Hospital
Dr De Angeli is a Senior Scientist at the Molecular Genetics Laboratory (head: Prof. Bernd Wissinger), Centre for Ophthalmology at the University Hospital Tübingen. Dedicated to pioneering translational therapies for inherited retinal dystrophies, he leads the pre-clinical research effort leveraging cutting-edge CRISPR/Cas-based editing techniques alongside innovative antisense oligonucleotide strategies.
Dr Maarten Geurts
Postdoctoral Fellow at the Princess Maxima Center for Pediatric Oncology
Dr Maarten Geurts is a molecular biologist with strong interest in genome engineering. During his Master studies, Maarten undertook an internship under joined supervision of Professor George Church at Harvard Medical School and Professor David R. Liu at the Broad Institute of Harvard and MIT. Here he saw the potential of CRISPR and wanted to use this powerful genome editing tool in more complex model systems. Thus, after finishing his Master’s in 2017 (cum laude), he joined the laboratory of Professor Hans Clevers at the Hubrecht Institute in Utrecht to apply CRISPR tools to human adult stem cell-derived organoids.
His main focus is now to both scale up genome engineering technologies as well as make them more generally applicable across model systems.
Related topics
Disease Research, Ex Vivo, Genome Editing, Screening
Related organisations
Princess Maxima Center for Pediatric Oncology, Tubingen University Hospital
